Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gubra ASHAM:PI3 +3.54%53 EV-to-OCF is 2.80 as of Jul. 21, 2026, which is 95% below its 10-year median of 61.85. GuruFocus rates HAM:PI3 with a GF Score™ of 53/100 and a GF Value™ of €388.86 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, Gubra AS ranks worse than 79.38% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Gubra AS's Enterprise Value is €643.3 Mil.
Gubra AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €229.6 Mil. Therefore, Gubra AS's EV-to-OCF for today is 2.80.
The historical rank and industry rank for Gubra AS's EV-to-OCF or its related term are showing as below:
HAM:PI3'
s EV-to-OCF Range Over the Past 10 Years
Min: -207.08 Med: 61.85 Max: 2098.56
Current: 2.71
During the past 7 years, the highest EV-to-OCF of Gubra AS was 2098.56. The lowest was -207.08. And the median was 61.85.
HAM:PI3's EV-to-OCF is ranked worse than 79.38% of 1411
companies
in the Biotechnology industry
Industry Median: -3.26
vs HAM:PI3: 2.71
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gubra AS's share price for today is €47.32.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gubra AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €13.767.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Gubra AS EV-to-OCF Related Terms
Gubra AS EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Gubra AS's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gubra AS's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Gubra AS's EV-to-OCF falls into.
Gubra AS's current Enterprise Value is €643.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gubra AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €229.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gubra AS (HAM:PI3) has a EV-to-OCF of 2.80 as of Jul. 21, 2026. This is 95% below median its historical median of 61.85. According to the industry distribution chart, Gubra AS ranks #1120 out of 1411 companies in the Biotechnology industry, placing it in the top 79.4%.
Is Gubra AS's EV-to-OCF too high?
Gubra AS's current EV-to-OCF of 2.80 is 95% below median its 10-year median of 61.85. Based on the distribution chart, Gubra AS ranks #1120 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gubra AS has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #1120 out of 1411 companies for EV-to-OCF. This places Gubra AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Gubra AS's current EV-to-OCF is 2.80, which is 95% below median its own 10-year median of 61.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (HAM:PI3) is currently considered Possible Value Trap. The stock's GF Value™ is €388.86, compared to a current price of €47.32 — trading 87.8% below its estimated fair value. The current EV-to-OCF is 2.80, which is 95% below median its 10-year median of 61.85. Gubra AS's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Gubra AS (HAM:PI3), the current EV-to-OCF is 2.80 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (HAM:PI3) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued.
The current stock price of €47.32 is trading 87.8% below its estimated GF Value™ of €388.86.
GuruFocus considers Gubra AS to be Possible Value Trap.
Key valuation signals for HAM:PI3:
EV-to-OCF: 2.80 (95% below median its 10-year median of 61.85)
GF Value™: €388.86 vs. price of €47.32 (87.8% below fair value)
No single metric tells the full story. See the HAM:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
53GF Score
Get the complete analysis for HAM:PI3
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:PI3 has been successfully added to your 
